Screener
TransMedics Group, Inc. TMDX Non Us — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206453
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Liver total revenue | 138,970 | 108,715 |
| Total United States OCS transplant revenue | 167,024 | 138,617 |
| All other countries | ||
| Lung revenue | 627 | 375 |
| Heart revenue | 5,011 | 3,550 |
| Liver revenue | 10 | 140 |
| Total all other countries OCS transplant revenue | 5,648 | 4,065 |
| Total OCS transplant revenue | $172,672 | $142,682 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is TransMedics Group, Inc.'s non us — revenue?
- TransMedics Group, Inc. (TMDX) reported non us — revenue of $5.65M in Q1 2026.
- What does non us — revenue mean?
- This metric represents the total revenue generated from sales and services provided to customers located outside of the company's primary domestic market. It serves as a key indicator of the company's international market penetration and the global scalability of its medical technology solutions. Monitoring this figure helps investors assess geographic diversification and the success of expansion strategies into foreign healthcare systems.
Ask your AI about TransMedics Group, Inc.'s non us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude